Respira Technologies is a company focus on aerosol science and biotechnology, and produces platform device. It has recently appointed Brian W. Quigley, who works 16 years in Altria Group, as its Chief Operating Officer from July 1. From 2012 to 2018, Quigley served as CEO at Altria and mainly engaged in the smokeless tobacco business. According to a press release, Altria’s business values nearly $2.3 billion, with more than 800 employees.
Quigley will be responsible for promoting the operational strategy, the regulatory approach of Respira, and commercial campaigns in the future. He will also contribute at the development of pharmaceutical applications through cooperation with other companies, or facilities, which may disrupt the contemporary tobacco market and nicotine replacement therapy (NRTs) market.
Respira has already produced two proprietary drug delivery platforms. One is a zero heat aerosol technology named RespiRx, and the other is a low heat aerosol technology, called Wave. Both technology platforms are designed for safe aerosol-based delivery of drugs to end-users and patients, without any harmful derivatives and compounds.
According to a report, Respira’s device platforms are produced to reduce harmful tobacco products and pharmaceutical drug delivery. Moreover, these device platforms contain applications in nicotine replacement therapies. Hence, the market for Respira may value about $1 trillion.
Respira’s founder and CEO, Mario Danek, said:
“We are thrilled to have Brian join the Respira team as we prepare to enter the commercial phase of our company’s growth… Brian’s vocal leadership for responsible industry practices and harm-reduction combined with his impressive track record of driving business performance in FDA regulated businesses make him the perfect leader for the next phase of growth for our unique product platforms.”
Quigley is excited to be joining Respira Technologies and looking for a new journey:
“I look forward to working with our team, investors, and partners as we prepare to commercialize our proprietary drug delivery platforms,” said Quigley. “My goal is to help improve public health and patient outcomes across a range of inhalable therapeutic applications, including tobacco cessation and the reduction of risk associated with tobacco use.”
This article is issued by vaporvoice, for more information, please check: